UNITED THERAPEUTICS Corp

United Therapeutics Corporation (NASDAQ: UTHR) is a biopharmaceutical company dedicated to developing innovative therapies for patients with serious diseases and unmet medical needs, with a particular focus on pulmonary arterial hypertension and organ transplantation technologies. The company operates as a public benefit corporation with an explicit mission to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.

The company's commercial product portfolio generates the majority of revenues through pulmonary hypertension treatments. Tyvaso DPI and Nebulized Tyvaso, both formulations of treprostinil, represent the largest revenue contributor at 59 percent of total revenues. Remodulin, another treprostinil formulation for continuous infusion, accounts for 17 percent of revenues, while Orenitram, an oral prostacyclin analogue, represents 16 percent. The company also markets Adcirca, a phosphodiesterase type 5 inhibitor, and Unituxin, a monoclonal antibody for high-risk neuroblastoma, which together comprise approximately eight percent of revenues. These products are distributed through specialty pharmaceutical channels in the United States and internationally.

Beyond commercial pharmaceuticals, United Therapeutics operates an extensive research and development pipeline focused on expanding treatment options for pulmonary fibrosis conditions and developing next-generation therapies. The company is advancing clinical programs including ralinepag, an oral prostacyclin receptor agonist in phase 3 development, and nebulized treprostinil formulations for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.

The company's organ manufacturing and transplantation division represents a significant strategic initiative. This includes xenotransplantation programs developing gene-edited porcine organs, regenerative medicine platforms through subsidiaries Miromatrix and IVIVA focused on manufactured kidney and liver alternatives, and ex vivo lung perfusion services through Lung Bioengineering. The company also invests in sustainable organ delivery infrastructure, including electric and hydrogen-electric aircraft development partnerships.

United Therapeutics maintains operations across multiple locations including principal executive offices in Silver Spring, Maryland and Durham, North Carolina, with additional facilities supporting organ manufacturing, research, and clinical operations nationwide.